HRO-761

Highest phase reached

Phase 1

Drug type

Small molecule

Listing at source: Listed

Highest phase reached: Phase 1
www.ebi.ac.uk

Drug type: Small molecule
www.ebi.ac.uk

Drug name: HRO-761
www.ebi.ac.uk

Molecular weight: 702.09
www.ebi.ac.uk

Structure (SMILES): CCc1c(N2CCN(C(=O)c3ncnc(C)c3O)CC2)c(=O)n2nc(C3=CCOCC3)nc2n1CC(=O)Nc1ccc(C(F)(F)F)cc1Cl
www.ebi.ac.uk

hro 761
HRO 761 [WHO-DD]
hro 761 who dd
Hro-761
HRO-761
hro761
Hro761
HRO761
romoverlib
Romoverlib
romoverlib [INN]
romoverlib inn
werner syndrome recq helicase in 1
WERNER SYNDROME RECQ HELICASE-IN-1

CAS registry numbers

2869954-34-5

ChEMBL ID: CHEMBL6068555
www.ebi.ac.uk

InChIKey: XKYVECRUZPCRQR-UHFFFAOYSA-N
www.ebi.ac.uk

PubChem compound IDs

166140536

FDA ingredient codes (UNII)

SCH4CP6PRC

First in class: No
Orphan designation: No

Pharmacology name: romoverlib
Type: Synthetic organic

Action type
Inhibitor
Target
WRN RecQ like helicase
Gene symbol
WRN RecQ like helicase
Action
Inhibition
Action type
Inhibitor
Target
WRN RecQ like helicase
Gene symbol
WRN
Protein identifier
Q14191
Median affinity
7
Affinity units
pIC50

Investigated indications

Condition
Colorectal Neoplasms
Highest recorded phase
1
Condition identifier
EFO:0000365
Subject identifier
D015179

Trial references

NCT05838768
clinicaltrials.gov

Hydrogen bond acceptors: 12
Hydrogen bond donors: 2
Polar surface area: 160.08
Calculated partition coefficient (ALogP): 3.33
Calculated partition coefficient (XLogP): 4
Prodrug: No
Chirality: Achiral
Inorganic: No
Rule-of-five violations: 2
Rotatable bonds: 7
Heavy atoms: 49
Molecular formula: C31H31ClF3N9O5
Monoisotopic mass: 701.2088773
Natural product: No

Recorded assays: 76
Active assays: 10

Active assay types

Confirmatory

Related records

Trials (1)

Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.

In development for (1)

Colorectal adenocarcinoma Phase 1

Targets (1)

WRN